image: Targeting Phage Therapy will welcome 73 presentations, including 25 major communications. view more
Credit: Targeting Phage Therapy
The 6th World Conference on Targeting Phage Therapy 2023 which will be held in Paris on June 1-2 will welcome more than 70 communications (major, short and poster presentations), and gather more than 150 international in-person and virtual participants from 31 countries.
Targeting Phage Therapy 2023: Strategic Questions
Phage Therapy 2023’s aim is to present the most recent advances on phage therapy within different sessions and topics. Each speaker will highlight where we are now and where we are heading. We believe that phages will be the hottest topic not only to combat infection and antibiotic resistance, but also to modulate our microbiota.
The chairmen of the scientific committee, Domenico Frezza (University of Roma Tor Vergata, Italy) and Marvin Edeas (INSERM – Institut Cochin, Université de Paris, France) stated:
“We will discuss many strategic aspects such as: where is the place of phages in our health map? We will initiate the discussion about potential clinical applications of phages in non-communicable human diseases. We will also debate the impact of phages on microbiome.”
Get access to the final agenda and speakers.
27 posters will be presented during the meeting. Check the list of posters of Phage Therapy 2023.
PHIOGEN, a university spin-off will be launching at Targeting Phage Therapy 2023
Ambitious new biotech venture PHIOGEN has developed a world-first technology platform that mobilizes the natural power of bacteriophages to tackle critical and life-threatening infections and marks a significant medical breakthrough for countering the global threat of antimicrobial resistance. The company will make its debut at the 6th World Conference on Targeting Phage Therapy in Paris, June 1-2, 2023, when more details will be unveiled.
The globally renowned research team behind PHIOGEN is housed in the world’s largest medical complex inside the prestigious Texas Medical Center’s Innovation Hub in Houston, Texas.
PHIOGEN is a spin-off company from Baylor College of Medicine’s TAILOR Labs, one of the United States’ only academic phage therapy centers, built on over a decade’s worth of revolutionary research that is now being commercialized to treat populations of patients.
PHIOGEN’s proprietary first-of-its-kind technology platform is capable of discovering and screening, at-scale, naturally occurring bacteriophages, singling out those with elite bacteria-fighting abilities, and directing biological changes to evolve the phage into antimicrobials which overcome resistance.
This technology creates a new business model for phage therapy as the group is able to create products which treat populations of people instead of on a per patient basis. By optimizing nature’s defenders, the team has produced unprecedented phage treatments which have already successfully saved the lives of several patients in FDA approved compassionate use cases.
Amanda Burkardt, CEO at PHIOGEN, said: “Nothing about our treatments is fabricated, it boils down to creating natural environments that mimic real-life infections, driving biological changes to create "super phages” against the superbugs. As a result, we receive high-performing phage fighters that are trained and ready to deliver safe and effective treatments for clinical applications.”
This new methodology holds the potential to play a major role in tackling the ongoing global health crisis of antimicrobial resistance dubbed ‘the silent pandemic’, which the World Health Organization (WHO) expects to be responsible for 10 million deaths annually by 2050.
PHIOGEN’s R&D efforts are led by acclaimed phage researcher Dr. Anthony Maresso, founder of TAILOR Labs and an associate professor at Baylor College of Medicine, whose phage therapy work has attracted funding of more than $5 million to date.
The WHO deems drug resistant infections as one of the top 10 global public health threats facing humanity with estimates of over 5 million deaths worldwide attributed to antibiotic resistant infections.
“Our patented technique of evolving the natural fighting power of bacteriophages creates a new paradigm in phage therapy where natural lytic cocktails carry the same advantages as fully synthetic phage and can be used to treat entire patient populations,” added Burkardt.
“Rising antibiotic resistance is one of the greatest health challenges of modern times. In real terms, our safe and effective phage treatments have the potential to transform clinical outcomes and save lives.”
Amanda Burkardt will further develop this technique and the spin-off during the conference, with a short talk: “Creating Patient Ready Products in a Remedy Ready World”.
Other Supporters and Innovations
Armata Pharmaceuticals and BiomX will share the results of their latest clinical trials
Mina Pastagia, Armata Pharmaceuticals, USA
Safety, Pharmacokinetics, and Antibacterial Activity of AP-PA02 Multi-phage Cocktail in Patients with Cystic Fibrosis and Chronic Pulmonary Pseudomonas aeruginosa Infection (SWARM-P.a. Clinical Trial)
Iddo Nadav Weiner, VP of Research at BiomX, Israel
A Phase 1b/2a Randomized, Double-blind, Placebo-controlled Study Evaluating Nebulized Phage Therapy in Cystic Fibrosis Subjects with Chronic Pseudomonas Aeruginosa Pulmonary Infection
Cellexus will present the use of their CellMaker system in GMP production
Adam Ostrowski, Cellexus, United Kingdom
Implementating GMP Manufacturing for Phage Therapy
Come and Network with 150+ Attendees
Phiogen (USA), Armata Pharmaceuticals (USA), BiomX (Israel), Cellexus (UK), Aparon (UK), AusHealth (Australia), Biochimpharm JSC (Georgia), BIOCODEX (Paris), BIOMERIEUX SA (France), COBIK (Slovenia), ERYTECH Pharma (France), H Venture Partners (USA), Intralytix, Inc. (USA), MB Pharma s.r.o. (Czech Republic), Microbiotix Inc. (USA), Optipharm Inc. (Republic of Korea), Phage Consulting, Phagos (France), Pherecydes Pharma (France), Proteon Pharmaceuticals S.A. (Poland), R.E.D. Laboratories (Belgium), Resistell (Switzerland), Rime Bioinformatics (France), SET Medikal (Turkey), Vésale Bioscience (Belgium), Vitalis Phage Therapy (India), Adam Mickiewicz University, Agricultural University of Athens, Amrita University, Azabu University, Bacteriophage.news, Baylor College of Medicine, Bhabha Atomic Research Centre, Biological Research Centre, Szeged, Campus Universitaire de Maubeuge, Centre International de Recherche en Infectiologie, Phage Consulting, Phage Directory, Pharmabiotic Research Institute (PRI),Polish Academy of Sciences, and others.
Contributing partner
PHAGE Therapy, Applications, and Research Journal is the Official Partner of Targeting Phage Therapy 2023.
Attendees will have the chance to network with the Editor in Chief, Martha Clokie, during Targeting Phage Therapy 2023 and discuss about future collaboration.
For more information about the conference program, speakers, venue and more: www.phagetherapy-site.com.
About PHIOGEN
PHIOGEN™ is a trademark of PHIOGEN INC. PHIOGEN is an innovative biotech company housed in the Texas Medical Center’s Innovation Hub and is committed to using proven technology to deliver patient-ready bacteriophage products to tackle the most deadly and serious bacterial infections facing our world. PHIOGEN’s world-class patented process has received early proof of concept validation through several in vivo studies as well as use in patients under FDA approved compassionate use cases.
For more information: www.phiogenpharma.co